Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Samsung Biologics
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
60.0%
+7.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:DominantThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Lonza
Competitor Displacement Rate
15.0%
Competitors are displacing Samsung Biologics in 15.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Samsung Biologics, a leading CDMO, competes fiercely with established global players who have extensive manufacturing capacities and long-standing client relationships in the biopharmaceutical industry.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[lonza.com][catalent.com]⚠️ Identified Vulnerability:Capacity Expansion
Primary Threat Identified:Lonza
Target Persona:Biotech companies seeking manufacturing partners
🚨 Threat Velocity:6/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)